RV-PA uncoupling is associated with increased mortality in transthyretin amyloid cardiomyopathy treated with tafamidis

被引:0
|
作者
Schwarting, Stephanie K. [1 ,2 ]
Poledniczek, Michael [2 ,3 ]
Metodiev, Yuliyan [1 ]
Stolz, Lukas [1 ]
Hofmann, Eva [2 ]
Hegenbart, Ute [4 ]
Schoenland, Stefan [4 ]
Kaeaeb, Stefan [1 ,5 ]
Massberg, Steffen [1 ]
Frey, Norbert [2 ]
Aus Dem Siepen, Fabian [2 ]
机构
[1] LMU Univ Hosp Munich, Dept Med 1, Marchionini str 15, D-81377 Munich, Germany
[2] Univ Hosp Heidelberg, Dept Cardiol Angiol & Resp Med, Neuenheimer Feld 410, Heidelberg, Germany
[3] Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Vienna, Austria
[4] Univ Hosp Heidelberg, Dept Internal Medicine5, Neuenheimer Feld 410, Heidelberg, Germany
[5] European Reference Network Rare Low Prevalence & C, Amsterdam, Netherlands
关键词
RV-PA coupling; Amyloidosis; Transthyretin; Echocardiography; TAPSE/PASP-ratio; HEART-FAILURE; CLINICAL-OUTCOMES; PROGNOSTIC VALUE; REPAIR; IMPACT;
D O I
10.1007/s00392-024-02576-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The right ventricle to pulmonary artery coupling (RV-PAc) describes the right ventricle's ability to adjust to an increased afterload. In case of transthyretin amyloid cardiomyopathy (ATTR-CM), impaired RV-PAc can result from increased left ventricular diastolic stiffness due to fibril deposition. Objectives While RV-PAc is a validated prognostic parameter in pulmonary arterial hypertension (PAH), its prognostic relevance in ATTR-CM remains unknown. We sought to evaluate the prognostic implications of impaired RV-PAc on survival in ATTR-CM. Methods In this multicentre study, RV-PAc was investigated by the echocardiographic surrogate of ratio of tricuspid annular plane systolic excursion to estimated pulmonary arterial systolic pressure (TAPSE/PASP) in 418 ATTR-CM patients, all treated with a TTR stabilizer. The primary outcome was all-cause mortality. Results Within a median time of 1.52 [IQR 0.72-2.56] years after diagnosis, 49 (11.7%) patients died. In multivariate Cox regression analysis impaired RV-PAc was a strong independent predictor of mortality (Hazard Ratio (HR) 2.16, 95% Confidence Interval (CI) 1.14-4.07, p = 0.018). RV-PAc ratio at first presentation emerged as a robust marker for risk stratification with a determined optimal cut-off of 0.382 mm/mmHg (area under the curve (AUC) 0.73, 95% CI 0.65-0.81). Patients with RV-PAc ratio <= 0.382 mm/mmHg exhibited significantly lower survival (HR 4.17, 95% CI 2.21-7.87, p < 0.001) within 3 years of follow up than those with RV-PAc ratio above the cut-off (Graphical Abstract). Conclusion Impaired adaptation of the RV to increased afterload is associated with worse outcome in ATTR-CM patients. RV-PAc ratio can serve as an echocardiographic predictor for all-cause mortality. Therefore, the determination of RV-PAc could improve risk stratification for ATTR-CM patients.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy
    Rettl, Rene
    Duca, Franz
    Binder, Christina
    Dachs, Theresa-Marie
    Cherouny, Bernhard
    Ligios, Luciana Camuz
    Mann, Christopher
    Schrutka, Lore
    Dalos, Daniel
    Charwat-Resl, Silvia
    Eslam, Roza Badr
    Kastner, Johannes
    Bonderman, Diana
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2023, 30 (01): : 127 - 137
  • [32] Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
    Li, Benjamin
    Alvir, Jose
    Stewart, Michelle
    CARDIOLOGY AND THERAPY, 2020, 9 (02) : 535 - 540
  • [33] Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
    Benjamin Li
    Jose Alvir
    Michelle Stewart
    Cardiology and Therapy, 2020, 9 : 535 - 540
  • [34] Benefits and Risks Associated with Mineralocorticoid Receptor Antagonists in Tafamidis-treated Transthyretin Amyloid Cardiomyopathy: A RealWorld Analysis
    Chi, Kuan Yu
    Borkowski, Pawel
    Osabutey, Anita
    Varrias, Dimitrios
    Song, Junmin
    Chang, Yu
    Madan, Shivank
    Patel, Snehal
    CIRCULATION, 2024, 150
  • [35] Safety and efficacy of tafamidis in Chinese patients with transthyretin amyloid cardiomyopathy
    Tian, Zhuang
    Peng, Daoquan
    Ma, Wei
    Yan, Jiangtao
    Wang, Jian'an
    Jin, Wei
    Tang, Yida
    Liu, Ying
    Jia, Caiping
    Gao, Yingxu
    Sun, Qiankun
    Angeli, Franca S.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S2 - S3
  • [36] Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
    Kazi, Dhruv S.
    Bellows, Brandon K.
    Baron, Suzanne J.
    Shen, Changyu
    Cohen, David J.
    Spertus, John A.
    Yeh, Robert W.
    Arnold, Suzanne V.
    Sperry, Brett W.
    Maurer, Mathew S.
    Shah, Sanjiv J.
    CIRCULATION, 2020, 141 (15) : 1214 - 1224
  • [37] Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report
    Fujita, Teppei
    Inomata, Takayuki
    Kaida, Toyoji
    Iida, Yuichirou
    Ikeda, Yuki
    Nabeta, Takeru
    Ishii, Shunsuke
    Maekawa, Emi
    Naruke, Takashi
    Koitabashi, Toshimi
    Kitamura, Eiji
    Sekijima, Yoshiki
    Ako, Junya
    CARDIOLOGY, 2017, 137 (02) : 74 - 77
  • [38] Tafamidis Should Be Accessible for All Patients With Transthyretin Amyloid Cardiomyopathy
    Psotka, Mitchell A.
    JACC-HEART FAILURE, 2021, 9 (02) : 124 - 126
  • [39] Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
    Falk, Rodney H.
    EUROPEAN HEART JOURNAL, 2019, 40 (12) : 1009 - 1012
  • [40] Change in echocardiography in patients with transthyretin amyloid cardiomyopathy with tafamidis treatment
    Morioka, M.
    Takashio, S.
    Fujiyama, H.
    Oike, F.
    Hanatani, S.
    Usuku, H.
    Yamamoto, E.
    Matsushita, K.
    Tsujita, K.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1764 - 1764